These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26070652)

  • 1. Comparison of conventional L-thyroxine withdrawal and moderate hypothyroidism in preparation for whole-body 131-I scan and thyroglobulin testing.
    Marturano I; Russo M; Spadaro A; Latina A; Malandrino P; Regalbuto C
    J Endocrinol Invest; 2015 Sep; 38(9):1017-22. PubMed ID: 26070652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
    Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
    Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal.
    Vaiano A; Claudio Traino A; Boni G; Grosso M; Lazzeri P; Colato C; Davì MV; Francia G; Lazzeri M; Mariani G; Ferdeghini M
    Nucl Med Commun; 2007 Mar; 28(3):215-23. PubMed ID: 17264781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moderate hypothyroidism in preparation for whole body 131I scintiscans and thyroglobulin testing.
    Guimaraes V; DeGroot LJ
    Thyroid; 1996 Apr; 6(2):69-73. PubMed ID: 8733874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute changes in clinical parameters and thyroid function peripheral markers following L-T4 withdrawal in patients totally thyroidectomized for thyroid cancer.
    Regalbuto C; Alagona C; Maiorana R; Di Paola R; Cianci M; Alagona G; Sapienza S; Vigneri R; Pezzino V
    J Endocrinol Invest; 2006 Jan; 29(1):32-40. PubMed ID: 16553031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
    Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
    Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
    J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing thyroid cancer without thyroxine withdrawal.
    Rosário PW; Vasconcelos FP; Cardoso LD; Lauria MW; Rezende LL; Padrão EL; Barroso AL; Guimarães VC; Purisch S
    Arq Bras Endocrinol Metabol; 2006 Feb; 50(1):91-6. PubMed ID: 16628280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of Hormone Withdrawal in Children Undergoing 131I Whole-Body Scans for Thyroid Cancer.
    Turpin S; Lambert R; Deal C
    Horm Res Paediatr; 2016; 86(6):410-415. PubMed ID: 27902975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer.
    Burmeister LA; Goumaz MO; Mariash CN; Oppenheimer JH
    J Clin Endocrinol Metab; 1992 Aug; 75(2):344-50. PubMed ID: 1639933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin.
    Valle LA; Gorodeski Baskin RL; Porter K; Sipos JA; Khawaja R; Ringel MD; Kloos RT
    Thyroid; 2013 Feb; 23(2):185-93. PubMed ID: 22978687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial.
    Leboeuf R; Perron P; Carpentier AC; Verreault J; Langlois MF
    Clin Endocrinol (Oxf); 2007 Dec; 67(6):839-44. PubMed ID: 17645577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seasonal variation of serum thyrotropin concentration and thyrotropin response to thyrotropin-releasing hormone in patients with primary hypothyroidism on constant replacement dosage of thyroxine.
    Konno N; Morikawa K
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1118-24. PubMed ID: 6804476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adequate thyroid-stimulating hormone levels after levothyroxine discontinuation in the follow-up of patients with well-differentiated thyroid carcinoma.
    Sánchez R; Espinosa-de-los-Monteros AL; Mendoza V; Brea E; Hernández I; Sosa E; Mercado M
    Arch Med Res; 2002; 33(5):478-81. PubMed ID: 12459319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved endothelial function and lipid profile compensate for impaired hemostatic and inflammatory status in iatrogenic chronic subclinical hyperthyroidism of thyroid cancer patients on L-t4 therapy.
    Gazdag A; Nagy EV; Burman KD; Paragh G; Jenei Z
    Exp Clin Endocrinol Diabetes; 2010 Jun; 118(6):381-7. PubMed ID: 19658059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in serum triiodothyronine, thyroxine, and thyrotropin during treatment with thyroxine in severe primary hypothyroidism.
    Maeda M; Kuzuya N; Masuyama Y; Imai Y; Ikeda H
    J Clin Endocrinol Metab; 1976 Jul; 43(1):10-7. PubMed ID: 947930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of thyroxine withdrawal in biochemical parameters and cardiac function and structure in patients with differentiated thyroid cancer.
    Chrisoulidou A; Pazaitou-Panayiotou K; Kaprara A; Platoyiannis D; Lafaras C; Boudina M; Georgiou E; Drimonitis A; Bischiniotis T; Vainas I
    Minerva Endocrinol; 2006 Jun; 31(2):173-8. PubMed ID: 16682940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyrotropin secretion in thyrotoxic and thyroxine-treated patients: assessment by a sensitive immunoenzymometric assay.
    Spencer CA; Lai-Rosenfeld AO; Guttler RB; LoPresti J; Marcus AO; Nimalasuriya A; Eigen A; Doss RC; Green BJ; Nicoloff JT
    J Clin Endocrinol Metab; 1986 Aug; 63(2):349-55. PubMed ID: 3088021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.